Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2017’, provides an overview of the Chronic Lymphocytic Leukemia (CLL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)

The report reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects

The report assesses Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

ABL Bio Inc

ACEA Biosciences Inc

ADC Therapeutics Sarl

Aeglea BioTherapeutics Inc

Altor BioScience Corp

Alvotech Iceland

Amgen Inc

Aptevo Therapeutics Inc

Aptose Biosciences Inc

Arno Therapeutics Inc

ArQule Inc

Astellas Pharma Inc

Astex Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Bionomics Ltd

Bionovis SA

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corp

Cellectar Biosciences Inc

Celltrion Inc

Cellular Biomedicine Group Inc

Coherus BioSciences Inc

Cyclacel Pharmaceuticals Inc

Debiopharm International SA

Deciphera Pharmaceuticals LLC

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

GeneaMed Ltd

Genentech Inc

Gilead Sciences Inc

Grupo Ferrer Internacional SA

Heidelberg Pharma GmbH

Humorigin Biotechnology Corp

Hutchison China MediTech Ltd

Hybrigenics SA

Igenica Biotherapeutics Inc

Immatics Biotechnologies GmbH

Immunomedics Inc

Incyte Corp

Inflection Biosciences Ltd

Innate Pharma SA

Innovent Biologics Inc

Johnson & Johnson

Juno Therapeutics Inc

Kancera AB

Karyopharm Therapeutics Inc

Kite Pharma Inc

Les Laboratoires Servier SAS

LFB SA

Ligand Pharmaceuticals Inc

Lymphocyte Activation Technologies SA

Medicenna Therapeutics Corp

MENTRIK Biotech LLC

Merck & Co Inc

Merck KGaA

Mesoblast Ltd

Millennium Pharmaceuticals Inc

MorphoSys AG

NantKwest Inc

Novartis AG

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

PEP-Therapy SAS

Pfizer Inc

PIQUR Therapeutics AG

Plexxikon Inc

Portola Pharmaceuticals Inc

Qurient Co Ltd

Redx Pharma Plc

Respiratorius AB

Rhizen Pharmaceuticals SA

Sandoz International GmbH

Sanofi

Selvita SA

Simcere Pharmaceutical Group

Sorrento Therapeutics Inc

Supratek Pharma Inc

Targazyme Inc

TG Therapeutics Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Tragara Pharmaceuticals Inc

Trillium Therapeutics Inc

United BioPharma Inc

Unum Therapeutics Inc

Verastem Inc

Viralytics Ltd

Xencor Inc

ZIOPHARM Oncology Inc

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Chronic Lymphocytic Leukemia (CLL) - Overview 8

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development 9

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 35

Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 51

Chronic Lymphocytic Leukemia (CLL) - Drug Profiles 102

Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 748

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 756

Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 758

Appendix 770

List of Tables

List of Tables

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2017 29

Number of Products under Development by Companies, H1 2017 31

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 32

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 33

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 34

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 35

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 36

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 37

Number of Products under Development by Universities/Institutes, H1 2017 38

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 39

Products under Development by Companies, H1 2017 40

Products under Development by Companies, H1 2017 (Contd..1), H1 2017 41

Products under Development by Companies, H1 2017 (Contd..2), H1 2017 42

Products under Development by Companies, H1 2017 (Contd..3), H1 2017 43

Products under Development by Companies, H1 2017 (Contd..4), H1 2017 44

Products under Development by Companies, H1 2017 (Contd..5), H1 2017 45

Products under Development by Companies, H1 2017 (Contd..6), H1 2017 46

Products under Development by Companies, H1 2017 (Contd..7), H1 2017 47

Products under Development by Companies, H1 2017 (Contd..8), H1 2017 48

Products under Development by Companies, H1 2017 (Contd..9), H1 2017 49

Products under Development by Companies, H1 2017 (Contd..10), H1 2017 50

Products under Development by Companies, H1 2017 (Contd..11), H1 2017 51

Products under Development by Universities/Institutes, H1 2017 52

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 54

Number of Products by Stage and Target, H1 2017 56

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 57

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 58

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 59

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 60

Number of Products by Stage and Mechanism of Action, H1 2017 62

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 63

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 64

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 65

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 66

Number of Products by Stage and Route of Administration, H1 2017 68

Number of Products by Stage and Molecule Type, H1 2017 70

Chronic Lymphocytic Leukemia (CLL) – Pipeline by 4SC AG, H1 2017 71

Chronic Lymphocytic Leukemia (CLL) – Pipeline by AbbVie Inc, H1 2017 72

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ABL Bio Inc, H1 2017 72

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ACEA Biosciences Inc, H1 2017 73

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ADC Therapeutics Sarl, H1 2017 73

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aeglea BioTherapeutics Inc, H1 2017 74

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Altor BioScience Corp, H1 2017 74

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Alvotech Iceland, H1 2017 75

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Amgen Inc, H1 2017 75

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aptevo Therapeutics Inc, H1 2017 76

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aptose Biosciences Inc, H1 2017 76

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Arno Therapeutics Inc, H1 2017 77

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ArQule Inc, H1 2017 77

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Astellas Pharma Inc, H1 2017 78

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Astex Pharmaceuticals Inc, H1 2017 78

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bayer AG, H1 2017 79

Chronic Lymphocytic Leukemia (CLL) – Pipeline by BeiGene Ltd, H1 2017 79

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 80

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bionomics Ltd, H1 2017 80

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bionovis SA, H1 2017 81

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Biothera Pharmaceutical Inc, H1 2017 81

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Boehringer Ingelheim GmbH, H1 2017 82

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bristol-Myers Squibb Company, H1 2017 82

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Celgene Corp, H1 2017 83

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Cellectar Biosciences Inc, H1 2017 84

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Celltrion Inc, H1 2017 84

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Cellular Biomedicine Group Inc, H1 2017 85

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Coherus BioSciences Inc, H1 2017 85

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017 86

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Debiopharm International SA, H1 2017 86

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 87

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Eli Lilly and Company, H1 2017 87

Chronic Lymphocytic Leukemia (CLL) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 88

Chronic Lymphocytic Leukemia (CLL) – Pipeline by GeneaMed Ltd, H1 2017 88

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Genentech Inc, H1 2017 89

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Gilead Sciences Inc, H1 2017 89

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Grupo Ferrer Internacional SA, H1 2017 90

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Heidelberg Pharma GmbH, H1 2017 90

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Humorigin Biotechnology Corp, H1 2017 90

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Hutchison China MediTech Ltd, H1 2017 91

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Hybrigenics SA, H1 2017 91

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Igenica Biotherapeutics Inc, H1 2017 92

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Immatics Biotechnologies GmbH, H1 2017 92

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Immunomedics Inc, H1 2017 93

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Incyte Corp, H1 2017 94

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Inflection Biosciences Ltd, H1 2017 94

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Innate Pharma SA, H1 2017 95

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Innovent Biologics Inc, H1 2017 95

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Johnson & Johnson, H1 2017 96

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Juno Therapeutics Inc, H1 2017 96

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Kancera AB, H1 2017 97

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Karyopharm Therapeutics Inc, H1 2017 98

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Kite Pharma Inc, H1 2017 98

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Les Laboratoires Servier SAS, H1 2017 99

Chronic Lymphocytic Leukemia (CLL) – Pipeline by LFB SA, H1 2017 99

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ligand Pharmaceuticals Inc, H1 2017 100

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Lymphocyte Activation Technologies SA, H1 2017 100

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Medicenna Therapeutics Corp, H1 2017 101

Chronic Lymphocytic Leukemia (CLL) – Pipeline by MENTRIK Biotech LLC, H1 2017 101

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Merck & Co Inc, H1 2017 102

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Merck KGaA, H1 2017 102

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Mesoblast Ltd, H1 2017 103

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Millennium Pharmaceuticals Inc, H1 2017 103

Chronic Lymphocytic Leukemia (CLL) – Pipeline by MorphoSys AG, H1 2017 104

Chronic Lymphocytic Leukemia (CLL) – Pipeline by NantKwest Inc, H1 2017 104

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Novartis AG, H1 2017 105

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Oncternal Therapeutics Inc, H1 2017 106

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 107

Chronic Lymphocytic Leukemia (CLL) – Pipeline by PEP-Therapy SAS, H1 2017 107

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Pfizer Inc, H1 2017 108

Chronic Lymphocytic Leukemia (CLL) – Pipeline by PIQUR Therapeutics AG, H1 2017 108

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Plexxikon Inc, H1 2017 109

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Portola Pharmaceuticals Inc, H1 2017 109

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Qurient Co Ltd, H1 2017 110

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Redx Pharma Plc, H1 2017 110

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Respiratorius AB, H1 2017 111

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Rhizen Pharmaceuticals SA, H1 2017 111

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Sandoz International GmbH, H1 2017 112

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Sanofi, H1 2017 112

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Selvita SA, H1 2017 113

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Simcere Pharmaceutical Group, H1 2017 113

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Sorrento Therapeutics Inc, H1 2017 114

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Supratek Pharma Inc, H1 2017 114

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Targazyme Inc, H1 2017 115

Chronic Lymphocytic Leukemia (CLL) – Pipeline by TG Therapeutics Inc, H1 2017 115

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Tolero Pharmaceuticals Inc, H1 2017 116

Chronic Lymphocytic Leukemia (CLL) – Pipeline by TRACON Pharmaceuticals Inc, H1 2017 116

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Tragara Pharmaceuticals Inc, H1 2017 117

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Trillium Therapeutics Inc, H1 2017 117

Chronic Lymphocytic Leukemia (CLL) – Pipeline by United BioPharma Inc, H1 2017 118

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Unum Therapeutics Inc, H1 2017 118

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Verastem Inc, H1 2017 119

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Viralytics Ltd, H1 2017 119

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Xencor Inc, H1 2017 120

Chronic Lymphocytic Leukemia (CLL) – Pipeline by ZIOPHARM Oncology Inc, H1 2017 120

Chronic Lymphocytic Leukemia (CLL) – Pipeline by Zymeworks Inc, H1 2017 121

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H1 2017 768

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H1 2017 (Contd..1), H1 2017 769

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H1 2017 (Contd..2), H1 2017 770

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H1 2017 (Contd..3), H1 2017 771

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H1 2017 (Contd..4), H1 2017 772

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H1 2017 (Contd..5), H1 2017 773

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H1 2017 (Contd..6), H1 2017 774

Chronic Lymphocytic Leukemia (CLL) – Dormant Projects, H1 2017 (Contd..7), H1 2017 775

Chronic Lymphocytic Leukemia (CLL) – Discontinued Products, H1 2017 776

Chronic Lymphocytic Leukemia (CLL) – Discontinued Products, H1 2017 (Contd..1), H1 2017 777

List of Figures

List of Figures

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2017 29

Number of Products under Development by Companies, H1 2017 30

Number of Products under Development by Universities/Institutes, H1 2017 38

Number of Products by Top 10 Targets, H1 2017 55

Number of Products by Stage and Top 10 Targets, H1 2017 55

Number of Products by Top 10 Mechanism of Actions, H1 2017 61

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 61

Number of Products by Top 10 Routes of Administration, H1 2017 67

Number of Products by Stage and Top 10 Routes of Administration, H1 2017 67

Number of Products by Top 10 Molecule Types, H1 2017 69

Number of Products by Stage and Top 10 Molecule Types, H1 2017 69

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports